117 related articles for article (PubMed ID: 10861451)
1. Identification and characterization of a Kunitz-type protease inhibitor in ascites fluid from patients with ovarian carcinoma.
Kobayashi H; Hirashima Y; Sun GW; Ohi H; Fujie M; Terao T
Int J Cancer; 2000 Jul; 87(1):44-54. PubMed ID: 10861451
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
3. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.
Akutagawa N; Nishikawa A; Iwasaki M; Fujimoto T; Teramoto M; Kitajima Y; Endo T; Shibuya M; Kudo R
Jpn J Cancer Res; 2002 Jun; 93(6):644-51. PubMed ID: 12079512
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
Anticancer Res; 2001; 21(4B):2983-7. PubMed ID: 11712798
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.
Nagy JA; Masse EM; Herzberg KT; Meyers MS; Yeo KT; Yeo TK; Sioussat TM; Dvorak HF
Cancer Res; 1995 Jan; 55(2):360-8. PubMed ID: 7812969
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M
Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595
[TBL] [Abstract][Full Text] [Related]
7. Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Tsukagoshi S; Saga Y; Suzuki N; Fujioka A; Nakagawa F; Fukushima M; Suzuki M
Int J Oncol; 2003 May; 22(5):961-7. PubMed ID: 12684660
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene.
Horiuchi A; Hayashi T; Kikuchi N; Hayashi A; Fuseya C; Shiozawa T; Konishi I
Int J Cancer; 2012 Oct; 131(8):1755-67. PubMed ID: 22287060
[TBL] [Abstract][Full Text] [Related]
10. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
Kobayashi H; Sugino D; She MY; Ohi H; Hirashima Y; Shinohara H; Fujie M; Shibata K; Terao T
Eur J Biochem; 1998 May; 253(3):817-26. PubMed ID: 9654084
[TBL] [Abstract][Full Text] [Related]
11. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
Yukita A; Asano M; Okamoto T; Mizutani S; Suzuki H
Anticancer Res; 2000; 20(1A):155-60. PubMed ID: 10769648
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
13. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
14. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
15. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.
Boocock CA; Charnock-Jones DS; Sharkey AM; McLaren J; Barker PJ; Wright KA; Twentyman PR; Smith SK
J Natl Cancer Inst; 1995 Apr; 87(7):506-16. PubMed ID: 7707437
[TBL] [Abstract][Full Text] [Related]
16. Neuregulin expression, function, and signaling in human ovarian cancer cells.
Gilmour LM; Macleod KG; McCaig A; Sewell JM; Gullick WJ; Smyth JF; Langdon SP
Clin Cancer Res; 2002 Dec; 8(12):3933-42. PubMed ID: 12473609
[TBL] [Abstract][Full Text] [Related]
17. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
18. p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells.
Pon YL; Zhou HY; Cheung AN; Ngan HY; Wong AS
Cancer Res; 2008 Aug; 68(16):6524-32. PubMed ID: 18701475
[TBL] [Abstract][Full Text] [Related]
19. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.
Wang-Johanning F; Liu J; Rycaj K; Huang M; Tsai K; Rosen DG; Chen DT; Lu DW; Barnhart KF; Johanning GL
Int J Cancer; 2007 Jan; 120(1):81-90. PubMed ID: 17013901
[TBL] [Abstract][Full Text] [Related]
20. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]